KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ionis Pharmaceuticals (IONS) Other Non Operating Income (2016 - 2025)

Ionis Pharmaceuticals (IONS) has 10 years of Other Non Operating Income data on record, last reported at -$16.3 million in Q4 2025.

  • For Q4 2025, Other Non Operating Income fell 5493.05% year-over-year to -$16.3 million; the TTM value through Dec 2025 reached -$15.4 million, down 1253.87%, while the annual FY2025 figure was -$15.4 million, 1253.87% down from the prior year.
  • Other Non Operating Income reached -$16.3 million in Q4 2025 per IONS's latest filing, down from $360000.0 in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $11.2 million in Q2 2023 and bottomed at -$16.3 million in Q4 2025.
  • Average Other Non Operating Income over 5 years is -$838650.0, with a median of $208500.0 recorded in 2022.
  • Peak YoY movement for Other Non Operating Income: plummeted 5689.93% in 2021, then soared 6133.33% in 2022.
  • A 5-year view of Other Non Operating Income shows it stood at -$477000.0 in 2021, then surged by 125.79% to $123000.0 in 2022, then soared by 93.5% to $238000.0 in 2023, then rose by 26.89% to $302000.0 in 2024, then tumbled by 5493.05% to -$16.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non Operating Income were -$16.3 million in Q4 2025, $360000.0 in Q3 2025, and $104000.0 in Q2 2025.